Boston Scientific Corporation (BSX)
Automate Your Wheel Strategy on BSX
With Tiblio's Option Bot, you can configure your own wheel strategy including BSX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BSX
- Rev/Share 13.0593
- Book/Share 15.2885
- PB 6.6696
- Debt/Equity 0.5365
- CurrentRatio 1.3721
- ROIC 0.0775
- MktCap 149593020400.0
- FreeCF/Share 2.2346
- PFCF 45.1806
- PE 53.6292
- Debt/Assets 0.2894
- DivYield 0
- ROE 0.128
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BSX | Erste Group | Buy | Hold | -- | -- | Oct. 3, 2025 |
| Upgrade | BSX | Oppenheimer | Perform | Outperform | -- | $125 | Sept. 8, 2025 |
| Initiation | BSX | Leerink Partners | -- | Outperform | -- | $118 | June 16, 2025 |
| Upgrade | BSX | Needham | Hold | Buy | -- | $113 | April 16, 2025 |
| Upgrade | BSX | Deutsche Bank | Hold | Buy | -- | $108 | Jan. 10, 2025 |
| Downgrade | BSX | Needham | Buy | Hold | -- | -- | Oct. 18, 2024 |
News
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Is Boston Scientific (BSX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.
Read More
Boston Scientific Sustains EP Momentum in Q3: Is More Upside Ahead?
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX's Q3 EP sales soar 63% on FARAPULSE momentum, FDA label expansion and rising global adoption.
Read More
Bet on 5 Top-Ranked Stocks With Rising P/E
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
Read More
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
Read More
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Published: October 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.
Read More
PAHC vs. BSX: Which Stock Is the Better Value Option?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Does Boston Scientific (BSX) Have the Potential to Rally 25.61% as Wall Street Analysts Expect?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 25.6% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Boston Scientific (BSX) is an Incredible Growth Stock: 3 Reasons Why
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Boston Scientific (BSX) could be a good stock pick from a technical perspective. BSX surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Read More
Boston Scientific (BSX) Recently Broke Out Above the 50-Day Moving Average
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Boston Scientific (BSX) is looking like an interesting pick, as it just reached a key level of support. BSX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Read More
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript
Published: October 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Boston Scientific Corporation (NYSE:BSX ) Q3 2025 Earnings Call October 22, 2025 8:00 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President & CEO Jonathan Monson - Executive VP & CFO Ken Stein - Senior VP & Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Joanne Wuensch - Citigroup Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Michael Polark - Wolfe Research, …
Read More
Boston Scientific (BSX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
Read More
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Boston Scientific (BSX) and Amarin (AMRN) have performed compared to their sector so far this year.
Read More
Unlocking Q3 Potential of Boston Scientific (BSX): Exploring Wall Street Estimates for Key Metrics
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
Will Robust Cardiovascular Performance Fuel BSX's Q3 Earnings?
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific's strong cardiovascular and MedSurg momentum, powered by innovations like WATCHMAN FLX Pro and AGENT DCB, could drive solid Q3 results.
Read More
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
PAHC or BSX: Which Is the Better Value Stock Right Now?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Medical technology stock picks for a ‘cautious' Q3: analysts
Published: October 07, 2025 by: Proactive Investors
Sentiment: Neutral
Citi analysts stressed being ‘cautious' on US medical technology stocks entering the third quarter, as the sector tends to underperform in September and October before recovering in November. In a note to clients on Tuesday, the analysts wrote that the sector was hit particularly hard this year as investors rotated out of healthcare and into technology.
Read More
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Down 10.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Boston Scientific (BSX)
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
Published: September 30, 2025 by: Proactive Investors
Sentiment: Positive
UBS analysts are ‘Overweight' the healthcare equipment sector, with a Number One ranking on their total scorecard. In a note to clients on Tuesday, the analysts wrote that healthcare equipment has had the highest growth rate historically, excluding technology, at a 9% compound annual growth rate (CAGR) and the sector's earnings per share are now trading 10% below trend.
Read More
PAHC vs. BSX: Which Stock Is the Better Value Option?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Is it a Prudent Move to Retain BSX Stock in Your Portfolio for Now?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Boston Scientific's acquisitions and WATCHMAN growth fuel optimism, but currency swings and macro pressures weigh on its outlook.
Read More
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
Read More
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
About Boston Scientific Corporation (BSX)
- IPO Date 1992-05-19
- Website https://www.bostonscientific.com
- Industry Medical - Devices
- CEO Michael F. Mahoney
- Employees 53000